Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Current Pharmaceutical Design
Title:Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Volume: 19 Issue: 32
Author(s): Charikleia Christakou and Evanthia Diamanti-Kandarakis
Affiliation:
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Export Options
About this article
Cite this article as:
Christakou Charikleia and Diamanti-Kandarakis Evanthia, Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320011
DOI https://dx.doi.org/10.2174/1381612811319320011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design Exosomes and Exosomal microRNAs in Age-associated Stroke
Current Vascular Pharmacology What Fans the Fire: Insights into Mechanisms of Leptin in Metabolic Syndrome- Associated Heart Diseases
Current Pharmaceutical Design Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design A Conceptual Framework of Comorbidity for Investigation in the Context of Psychiatric Disturbance
Current Psychiatry Reviews Solubilization and Antitumor Activity of Oleanolic Acid Lysinate
Current Analytical Chemistry Impact of Bread Made from Mix Cereals and Pulses on the Glycemic Profile in Type 2 Diabetic Patients - A Randomized Controlled Trial
Current Nutrition & Food Science The Anabolic Androgenic Steroid Testosterone Propionate Decreases Recognition Memory in Adult Male Rats
Current Psychopharmacology Bioactive Components and Pharmacological Action of Wikstroemia indica (L.) C. A. Mey and Its Clinical Application
Current Pharmaceutical Biotechnology Enhancing Cardiovascular Dynamics by Inhibition of Thrombospondin- 1/CD47 Signaling
Current Drug Targets Lysophosphatidic Acid and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design Diet Effects on Atherosclerosis in Mice
Current Drug Targets The Relation Between the Chemical Structure of Flavonoids and Their Estrogen-Like Activities
Current Medicinal Chemistry Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Medication Adherence of Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Considering the Psychosocial Factors, Health Literacy and Current Life Concerns of Patients
Current Rheumatology Reviews High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Revascularization vs. Optimal Medical Therapy in Women with NSTE-ACS
Current Pharmaceutical Design Guidelines and their Implementation: A Discussion Document Focused on the Best Approaches to Drive Improvement
Vascular Disease Prevention (Discontinued)